window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : August 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

oncology

  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Pierre Fabre moves closer to first-line approval for BRAFTOVI in BRAF-mutant metastatic colorectal cancer

    Pierre Fabre Laboratories has received a positive opinion from the [...]

    June 6, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE backs serplulimab for extensive-stage small cell lung cancer

    People with extensive-stage small cell lung cancer in England and [...]

    June 6, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Mestag Therapeutics doses first patient in Phase 1 STARLYS solid tumour trial

    Mestag Therapeutics has dosed the first patient in its Phase [...]

    May 28, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Protara reports durable 12-month responses for TARA-002 in Phase 2 bladder cancer trial

    Protara Therapeutics has reported updated 12-month data from its ongoing [...]

    May 19, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    AstraZeneca’s Imfinzi recommended by NICE for resectable gastric and gastro-oesophageal junction cancer

    AstraZeneca’s Imfinzi (durvalumab) has been recommended by NICE for use [...]

    May 14, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Allucent adds strategy leaders to expand therapeutic expertise

    Allucent has appointed new therapeutic strategy leaders across key disease [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    FoRx Therapeutics presents preclinical data on PARG inhibitor FORX-428 at ACS Spring 2026

    FoRx Therapeutics presents preclinical data on FORX-428, a PARG inhibitor [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    etherna intratumoral mRNA/LNP platform advances toward IND studies in non-melanoma skin cancer

    etherna, a biotech company specialising in mRNA and lipid nanoparticle [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Fennec presents real world data on Pedmark use in head and neck cancer

    Fennec Pharmaceuticals has presented real world data supporting the integration [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Scancell clears FDA IND for iSCIB1+ registrational Phase 3 trial in advanced melanoma

    Scancell Holdings has announced that the U.S. Food and Drug [...]

    May 5, 2026
Previous345Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • CellProthera and Alfresa sign MOU for ProtheraCytes Phase 3 trial in Japan
    Categories: Advanced Therapies, Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
  • FDA approves Moderna’s mRNA flu vaccine mFLUSIVA
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Vaderis raises $152M and starts Phase 3 trial of engasertib in HHT
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top